click enter text
initi outperform pt market power undeni
invest view tmo rel growth surg pharma valid
signal survey work tmo scale-up pharma/academ
channel achiev portfolio domin alongsid unmatch physic
e-commerce custom presenc yet price-to-earnings vs tool peer line recent
histori yield line peer agre growth
point market achiev estim
consensu estim achiev compound tmo higher
exposur consumables/rep revenu vs peer vs
averag heavier revenu mix biopharma academ bp
peer averag us bp
one critic flaw valuat consensu key gap model
medium term capit deploy drive high visibl medium term upsid
estim tmo medium term plan call capit deploy
 estim reflect deploy drive return
assum leverag level lower target
data point encourag custom indic appropri call
inflect academic/pharma sinc signal modest
acceler would off-set industrial/appli slow
survey confirm share gain key custom exhibit
valuat framework pt deriv forecast
target yield line tool group averag account
balanc high estim visibl slightli below-p near-term
growth methodolog detail industri report forecast
assum increment free cash deploy return
tmo capit deploy target
exhibit tmo margin expect grow
trade fundament data
upsid target
price
report limit sole use client wolf research pleas refer disclosur section locat end
report analyst certif import disclosur disclosur
page
win scale qualiti
domin forc tmo acceler last
three year reflect combin acceler e-
commerc traction part thank life
expand line-up exclus product
case truli new product includ fei
technolog case line extens
q-exact franchis tmo distribut
scale servic presenc unriv
pharma servic line-up includ manufactur
clinic trial develop one-of-a-kind
remark mani dynam emerg
within last year rapid evolut larg
compani understand aggreg
import still somewhat nascent tmo
object drive
consensu toward way
think remain case price-to-earnings vs tool
continu track band meaning
differ norm last year
offer highest visibl estim
achiev group consensu
model assum substanti fall-off balanc
sheet leverag conserv rel
page
yieldfcf compound-annual-growth-rate price-to-earnings premium tool median median mediancategori build
note peer growth calcul weight averag set exclud
exhibit shift toward life scienc revenu away
set broad share gain
bit secret sauc sustain share
gain consist see
survey work challeng intuit forecast
fortun articul seri notabl
step driven acceler share gain
late includ push harder corpor
account larg divers
enough negoti senior level larg
grow invest data scienc
identifi sell servic opportun local
facil india singapor china
articul harder push posit india
histor stronghold custom co-
develop effort includ product line
mass spec larg biotech compani
orbitrap mass spec
technolog appli market wat/agil
histor focus market-domin scale
china enabl closer tie integr
custom effort tmo china busi notabl
larger global sale
survey confirm outlook share gain academic/pharma lab survey lab
april assess apples-to-appl trend share key product categori survey continu
biannual seri look impli inflect market adopt technolog expect shift
alloc spend vendor seri remain consist share gainer though
trend evolv somewhat late sharper gain academ mass spec separ highest asp
item broad consist gain pharma
note survey conduct april pharma lab respond
note survey conduct april academ lab respond
page
anticip pharma market share chang previou month vs next month anticip academ market share chang previou month vs next month growth vs peer bp vs weight organ peer enu growth shift life scienc substitut cyclic enu mixacademic/gov biopharmadiagnosticsindu /appli life scienc
exhibit bioprocess volum forecast continu rise
exhibit govern spend health due acceler
acquisit prepar shift
secur revenu stream
posit current environ
last ten year tmo pharma revenu mix
track figur go
higher upcom close brammer
deal organ growth channel less
volatil small molecul
manufactur dynam domest china
polici industri pressur constrain capit
spend drive volatil waters/agil tmo
repeat revenu mix sale also
bp higher peer over-index
us proven benefit compani on-
shore project us rate similar
intern rate like work
given compani scale domest regard
industri trend tmo cyclic fallen sharpli
revenu industri end
market
semiconductor materials/min commerci
peak
exhibit bioprocess industri growth strong
combin manufactur clinic trial
servic busi one-of-a-kind offer
estim market present
anoth product happen
intern drug produc legaci
patheon platform gain share space
scale capit access offer higher degre
coordin certainti capac
synergi anoth variabl pthn
custom overlap
acquisit manufactur side
posit singl use grow faster
hsd bioprocess market well posit
benefit updraft outsourc offer
product abil local site
page
quantiti kg/yr forecast bulk kg productcommercialbla/maa/ndaphas spend health top feder select eu horizon fpchina estimate composit yoy revenu growth small large-cap mn total salesyoy sale growth biotechyoy bioprocess growth
exhibit outpac growth establish bioprocess
financi plan revis compani analyst
event last week call ep growth
includ benefit capit
deploy includ year
like manifest blend larg mid
size deal across line busi consensu
model ep next two year
clearli guid capit deploy
next four year model
presum leverag track lower
time sens model larg
line consensu item guidanc
impli like keep leverag
level higher mid/high singl digit return
addit guid bn capit could gener
addit ebit medium term
estim clear unlik consensu
model higher return interest incom
proxi capit deploy
cash balanc reflect presumpt lower
leverag target tmo intern plan
margin expans outlook rel
strength high visibl guid
bp omx per year organ fx
 introduc variabl trend model
slightli higher growth margin see
opportun materi minor linger
tailwind cost ration within previous
exhibit continu revis organ sale guidanc upward
page
analyst analyst analyst daywr estimate con organ organ growth organ growth organ growth mgn compound-annual-growth-rate incl categori organ growthindustri compound-annual-growth-rate compound-annual-growth-rate ashar model vs guidanc mn guidancewolf estimate
stabl environ life scienc
demand review seri candid
variabl tight relationship year
pharma strong seri
candid correl select index
constitu reflect mix region
sourc fund index incorpor us
consum spend trend european macro
instrument cost trend manufactur trend
healthcar europ
exhibit led organ revenu growth ls coverag exhibit organ growth forecast steadi
note differ organ revenu growth wolf
weight averag tool coverag
page
rel organ growth vs chang org revenue qtli yoy chang mthli yoy chang vs yoy chang org revenue pharma org chang org revenue qtli yoy chang mthli yoy chang vs yoy chang org revenue acad-gov mnth lag org organ growthyoystack
exhibit see way recur life scienc
exhibit outpac growth establish bioprocess
note refer bioprocess divis
exhibit tool pharma revenu exposur sub-categori
exhibit one highest life scienc exposur
tool coverag
note total life scienc defin sum academ
revenu total regul dx food env forens total
cyclic dx food env pertin industri
page
mix recur revenuesacademicpharmatotalsub-totaltot pharma salescro/cdmo salesr mfg small mol qa/qcsoftware/ servicessmal mol biotech/ larg wgtd exposur life sciencetot regulatedtot cyclicalexposur tool categori organ growthtmoindustrytmo compound-annual-growth-rate compound-annual-growth-rate
exhibit model consensu organ increment
margin growth onward
exhibit non-organ ebit margin moder
input less wolf estim inorgan margin growth adjust
exhibit organ ebit margin expans forecast sit
industri averag
note top bar repres report margin expans given year
includ affx pthn fei life
impacts/synergi relev year
exhibit model growth expand
note agil includ keysight bill fx ilab multiplicom
dilut pension chang bond yield includ charg
page
exhibit shift away relianc instrument
note organ growth consensu estim consensu nomin growth
estim less wolf estim inorgan impact revenu fx sell
day
exhibit net debt ebitda fallen despit busi
page
stack accel/decel organ growth momentum estimateswolfeconsensuscon wgtd diff con wgtd diff revenu instrumentsinstru intens vs conversionorgan margin build margin op increment alloc discontinu non-cash tax work share debt ebitdaavg
page
yieldfcf compound-annual-growth-rate ebitda compound-annual-growth-rate ev-ebitda vs estimate ebitda compound-annual-growth-rate tool price-to-earnings premium tool median median price-to-earnings premium compound-annual-growth-rate
page
note figur million unless state per-shar term
page
excl deal relat share fulli ebit increment
note figur million unless state per-shar term
page
note figur million unless state per-shar term
page
note figur million unless state per-shar term
page
work continu dc continu dc flowsstock cont dc cash share
